Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/208402
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrunet Mas, Eduard-
dc.contributor.authorGarcia Sagué, Belen-
dc.contributor.authorVela, Emli-
dc.contributor.authorMelcarne, Luigi-
dc.contributor.authorLlovet, Laura Patricia-
dc.contributor.authorPontes, Caridad-
dc.contributor.authorGarcía Iglesias, Pilar-
dc.contributor.authorPuy, Anna-
dc.contributor.authorLario, Sergio-
dc.contributor.authorRamirez Lazaro, Maria Jose-
dc.contributor.authorVilloria, Albert-
dc.contributor.authorBurisch, Johan-
dc.contributor.authorKaplan, Gilaad G.-
dc.contributor.authorCalvet, Xavier-
dc.date.accessioned2024-03-05T12:29:21Z-
dc.date.available2024-03-05T12:29:21Z-
dc.date.issued2024-02-14-
dc.identifier.issn1756-2848-
dc.identifier.urihttp://hdl.handle.net/2445/208402-
dc.description.abstractBackground: Inflammatory bowel disease (IBD) has a major economic impact on healthcare costs.Objectives: The aim of this study was to evaluate the current healthcare expenditure associated with IBD in a population-wide study in Catalonia.Design: Retrospective observational study.Methods: All patients with IBD included in the Catalan Health Surveillance System (CHSS) were considered eligible. The CHSS compiles data on more than 7 million individuals in 2020 (34,823 with IBD). Data on the use of healthcare resources and its economic impact were extracted applying the International Classification of Diseases, 10th revision, Clinical Modification codes (ICD-10-CM codes). Health expenditure, comorbidities, and hospitalization were calculated according to the standard costs of each service provided by the Department of Health of the Catalan government. The data on the IBD population were compared with non-IBD population adjusted for age, sex, and income level. IBD costs were recorded separately for Crohn's disease (CD) and ulcerative colitis (UC).Results: Prevalence of comorbidities was higher in patients with IBD than in those without. The risk of hospitalization was twice as high in the IBD population. The overall healthcare expenditure on IBD patients amounted to 164Meuro. The pharmacy cost represents the 60%. The average annual per capita expenditure on IBD patients was more than 3.4-fold higher (IBD 4200euro, non-IBD 1200euro). Average costs of UC were 3400euro and 5700euro for CD.Conclusion: The risk of comorbidities was twice as high in patients with IBD and their use of healthcare resources was also higher than that of their non-IBD counterparts. Per capita healthcare expenditure was approximately 3.4 times higher in the population with IBD.Trial registration: The study was not previously registered. Economic impact of inflammatory bowel disease in CataloniaThe manuscript includes data of the most recent epidemiologic data about the high economic impact of IBD in Catalonia.-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSAGE Publications-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1177/17562848231222344-
dc.relation.ispartofTherapeutic Advances in Gastroenterology, 2024, vol. 17-
dc.relation.urihttps://doi.org/10.1177/17562848231222344-
dc.rightscc by-nc (c) Brunet Mas, Eduard et al., 2024-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationMalalties inflamatòries intestinals-
dc.subject.classificationCatalunya-
dc.subject.otherInflammatory bowel diseases-
dc.subject.otherCatalonia-
dc.titleEconomic impact of inflammatory bowel disease in Catalonia: a population-based analysis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2024-02-26T12:48:41Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid38357537-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))



This item is licensed under a Creative Commons License Creative Commons